Company intelligence / Profile preview

Apeiron Group

Burlingame, California, United States

Ownership: Private
Development stage: Other

Overview

Apeiron Therapeutics (formerly Apeiron Biologics AG) is best known for co-developing Qarziba (dinutuximab beta), the only immunotherapy for high-risk neuroblastoma approved in Europe, and for its AI-driven drug discovery platform. The company was acquired by Ligand Pharmaceuticals in July 2024 for $100 million. Its operational R&D activities now reside in invIOs, a spin-off focused on developing novel immuno-oncology assets, while Apeiron retains a royalty position from Qarziba sales[3][4].

Therapeutic areas: Oncology
Modalities: Monoclonal antibodySmall moleculeCell therapy
Industry: Biotech

Partnerships

EUSA PharmaRecordatiChildren's Cancer Research Center (CCRI)European Neuroblastoma Research Network (SIOPEN)

Beyond the preview

Go deeper on Apeiron Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Apeiron Group.

Explore the full profile